ArticleWorld journal of urology2025
Can bladder MRI avoid systematic second TURBT for patients with high-risk NMIBC?
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Letter to the editor: can bladder MRI avoid systematic second TURBT for patients with high-risk NMIBC?World journal of urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesRepeat transurethral resection of bladder tumor (2nd -TURBT) is recommended for high-risk non-muscle invasive bladder cancer (HR-NMIBC) to reduce the risk of understaging and residual tumors. Despite its proven benefits, 2nd -TURBT remains an invasive and costly procedure. This study aimed to evaluate if bladder MRI, performed before initial TURBT (i-TURBT), could be in selected patient, a non-invasive alternative to 2nd -TURBT.
methodsData from 34 single-center patients who had MRI performed prior to i-TURBT and underwent 2nd -TURBT for HR-NMIBC between March 2020 and July 2024 were retrospectively collected.
resultsMpMRI demonstrated high accuracy in detecting muscle-invasive bladder cancer, with sensitivity, specificity, positive predictive value, and negative predictive value of 100% (95% CI 0.61-1), 96% (95% CI 0.82–0.99), 86% (95% CI 0.49–0.97), and 100% (95% CI 0.87-1), respectively. Among patients with mpMRI findings suggestive of NMIBC (n = 27), the residual tumor rate was 12% (n = 3). No residual tumor was found on 2nd-TURBT in patients with pTa tumor (n = 6) on i-TURBT and VIRADS ≤ 3, neither with pT1 tumor and detrusor muscle sampled on i-TURBT (n = 28), with unifocal VIRADS ≤ 3.
conclusionBladder MRI appears to be a valuable tool in HR-NMIBC management and could avoid 2nd -TURBT in selected patients, with a unifocal VIRADS ≤ 3 lesion and detrusor muscle sampled in i-TURBT.
Indexed as
Identifiers
41091212What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.